Treatment of cancer cells with 17-AAG, a Hsp90 inhibitor and an analog of geldanamycin, promotes degradation of varieties of p53 mutants (p53R175H, p53L194F, p53R273H, and p53R280K) and decreases viability of cells carrying mutant p53 (69). This evidence concerns the gene TP53 and cancer.